The mouse autosomal recessive mutation progressive motor neuronopathy (pmn) results in early onset motor neuron disease with rapidly progressive hindlimb paralysis, severe muscular wasting, and death at around 6 weeks of age. This mutant provides opportunities for testing novel therapeutic strategies, including the administration of trophic factors, to prevent the degeneration of diseased neurons. The construction of a strain expressing the pmn and the Extra-toe (Xt) phenotypes allows the detection, and therefore the treatment, of affected progeny before the onset of the clinical weakness. Electromyography is the most appropriate technique for a longitudinal study in which a given individual is examined repeatedly. We present the results of an electrophysiological and behavioral exploration of the pmn disease and show that electromyography is a powerful tool for following the course of the disease and evaluating potential therapies relevant to motor neuron diseases. r 1996 Academic Press, Inc.
INTRODUCTION
Considerable progress has been made in recent years in the understanding of the biological causes of motor neuron diseases (MND) 2 (Kuncl et al., 1992; Williams & Windebank, 1993) . Combined clinical and pathological studies have demonstrated that the signs of many neurological diseases result from the dysfunction and/or the death of particular populations of nerve cells in the central and/or peripheral nervous systems. In these diseases, defined subsets of neurons degenerate, resulting in a specific pattern of clinical manifestations.
To test new therapies, investigators have focused their effort on developing animal models of MND and measuring clinical, biological, and functional features so as to be able to evaluate disease severity and progression. Determining reference values, for both control and congenitally diseased animals, allows subsequent appraisal of therapy by testing whether and how the selected parameters are altered by the treatment.
